Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
Panelists discuss how amivantamab plus lazertinib therapy for EGFR-mutant non–small cell lung cancer has shown promising survival data while highlighting the importance of managing adverse events for improved quality of life.
EP: 1.Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
EP: 2.Overview of Study Design of the COCOON Trial
EP: 3.COCOON Baseline Characteristics
EP: 4.COCOON: Discussion of Clinical End Points and Dose Modifications
EP: 5.Initial Reactions to COCOON Study’s Dermatologic/Nail AE Reductions
EP: 6.Clinician Experiences: COCOON Regimen vs Traditional SoC AE Management
EP: 7.Measuring Impact: Observed Differences in Dermatologic AEs Between COCOON Protocol and Standard Approaches
EP: 8.Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
EP: 9.Operational Considerations: Workflow Adjustments and Monitoring Systems for Effective COCOON Implementation
EP: 10.COCOON in Practice: Patient Preparation, Key Insights, and Implementation Best Practices
Video content above is prompted by the following:
Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
Background
- Discussion between Alexander Spira, MD, PhD, FACP, FASCO, and Randi Rabin, MPH, MSc, PA-C
- Topic: Prevention of moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced non–small cell lung cancer treated with amivantamab plus lazertinib
- Referenced data from the COCOON trial presented at the European Lung Cancer Congress 2025
Clinical Experience
- Practitioners have extensive experience with amivantamab and lazertinib across multiple clinical trials (COCOON, CHRYSALIS 2, SKIPPirr, PALOMA 2 and 3).
- Overall positive experience reported for both providers and patients
- “Fantastic overall survival data” noted
Evolving Treatment Focus
- Field shifting from solely focusing on response rates and survival metrics to also emphasizing:
- Management of adverse events
- Quality of life measures
- Rationale: Improved tolerability increases adherence, which is essential for drug efficacy.
Patient Outcomes
- Patients on these medications reportedly maintain active lifestyles (travel, community involvement, physical activities).
- Quality of life improvements allow patients to continue normal activities while undergoing treatment.
Current Research Direction
- Focus on optimizing management rather than just administering treatment
- Specifically discussing the COCOON trial’s findings on skin/dermatologic adverse event management
- Related research includes infusion-related reaction management from the SKIPPirr trial
This summary reflects a discussion about managing adverse effects to improve both efficacy and quality of life for patients receiving amivantamab plus lazertinib combination therapy.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
